Novo Nordisk India Introduces Ozempic, Considering Socio-Economic Factors | Briefs

Novo Nordisk has officially launched Ozempic in India, a once-weekly GLP-1 receptor agonist for adults managing uncontrolled type 2 diabetes. Intended as an add-on therapy to diet and exercise, Ozempic arrives as India grapples with a rapidly increasing diabetes burden and generalized obesity.

Novo Nordisk Introduces Ozempic in India

Novo Nordisk has officially launched Ozempic (injectable semaglutide) in India. This marks the availability of a widely used once-weekly GLP-1 receptor agonist for adults dealing with uncontrolled type 2 diabetes. The company stated that Ozempic® is designed to supplement diet and exercise, arriving at a crucial time for India, which is experiencing a surge in diabetes cases.

According to WHO's 2023-24 estimates, India has 101 million individuals living with diabetes. An additional 136 million are classified as prediabetic, and 254 million are affected by generalized obesity. These figures underscore the pressing need for effective treatment solutions. Health tracking apps like Shotlee can help monitor blood sugar levels and medication adherence.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Get it onGoogle Play

Novo Nordisk India MD Vikrant Shrotriya pointed out that many patients face the dual challenge of diabetes and excess weight, making Ozempic a suitable therapeutic option. He also noted that the company is aware of India's socioeconomic realities. To improve accessibility, the medication has been priced at Rs 2,200 per week.

Source Information

Originally published by The Times of India.Read the original article →

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

Health & Wellness

Wegovy, Ozempic & Mounjaro: The Real Truth About Weight Loss Meds

A comprehensive guide to GLP-1 receptor agonists, understanding efficacy, managing side effects, and navigating the future of obesity treatment.

7 min read

Health & Wellness

Beyond Ozempic: The Future of Weight Loss & Metabolic Health Innovation

The GLP-1 revolution is just the beginning. This article delves into the cutting-edge advancements poised to reshape the future of weight loss and metabolic health, offering insights for patients and observers alike.

7 min read

Health & Wellness

Beyond Weight Loss: The Next Wave of GLP-1 Drugs

The revolutionary GLP-1 medications have transformed weight management, but the journey of innovation continues. Discover how upcoming drugs aim to enhance patient experience and outcomes.

7 min read

Same topic: Diabetes

All Diabetes articles →

Health & Wellness

Beyond Weight Loss: Do GLP-1 Drugs Impact Mental Health?

New research is exploring the surprising potential of GLP-1 receptor agonists, known for their role in diabetes and weight management, to also influence mental well-being. This article delves into the latest findings and what they mean for patients.

7 min read

Health & Wellness

Beyond BMI: Why Mounjaro Eligibility is More Complex Than You Think

Many assume BMI is the sole determinant for Mounjaro prescriptions, but the reality is far more nuanced. This article explores the comprehensive health criteria healthcare providers use to ensure safe and effective treatment.

6 min read

Health & Wellness

Beyond the Scale: Are GLP-1 Drugs Depleting Vital Nutrients?

While GLP-1 agonists are revolutionizing weight management, emerging research suggests a potential downside: nutrient deficiencies. This article delves into what the latest studies reveal about these vital nutrient gaps and how to address them.

6 min read

More in Health

Health & Wellness

Beyond Ozempic: A New Pill Targets Fat Metabolism Without Appetite Loss

A groundbreaking pill developed by researchers at Karolinska Institutet and Stockholm University offers a new avenue for treating type 2 diabetes and obesity. Unlike injectable GLP-1 agonists, this oral medication targets muscle metabolism to enhance fat burning and improve blood sugar control, aiming to circumvent common side effects.

7 min read

Health & Wellness

Pfizer's Berobenatide: A New Monthly GLP-1 for Weight Loss?

Pfizer's investigational GLP-1 receptor agonist, berobenatide, has shown promising results in Phase 2b trials for weight loss. This article delves into the data, its implications for obesity treatment, and what it means for Pfizer's investment outlook.

7 min read

Health & Wellness

Ozempic, Wegovy & Beyond: How GLP-1 Drugs Are Changing What We Eat

The rise of GLP-1 medications is profoundly altering consumer spending habits and food preferences, forcing the grocery industry to adapt. Discover the science behind these changes and how businesses are responding.

7 min read